Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Elon Musk
Donald Trump
Artificial Intelligence
World Cup
Social Media
Stock Markets
Nintendo
Apple
Crime
Baseball
Infrastructure
Published • loading... • Updated

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

Summary by endpoints.news
NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced it would buy Allergan's generics business ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
endpoints.newsendpoints.news

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced it would buy Allergan's generics business ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Thursday, June 5, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Innovation

Innovation

New York City

New York City

News
For You
SearchBlindspotLocal